Modality
mRNA
MOA
TROP-2 ADC
Target
Tau
Pathway
Lipid Met
Pancreatic CaPSP
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
Apr 2021
→ Mar 2026
Phase 2Current
NCT06245534
2,032 pts·Pancreatic Ca
2021-04→2026-03·Recruiting
2,032 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-241w agoPh2 Data· Pancreatic Ca
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2
Recruit…
Catalysts
Ph2 Data
2026-03-24 · 1w ago
Pancreatic Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06245534 | Phase 2 | Pancreatic Ca | Recruiting | 2032 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP | |
| Zoriosocimab | Akero | Approved | C5 |